New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 2, 2013
07:34 EDTHEBHemispherx, University of Pittsburgh collaborate on Chemokine Modulation program
Hemispherx Biopharma announced that it is supporting the University of Pittsburgh's National Institutes of Health funded study currently underway as part of the University's Chemokine Modulation Research initiative which includes Ampligen as an adjuvant. As part of this collaboration, Hemispherx has supplied clinical grade Ampligen to the University. This collaboration expands the company's current collaborations with several other comprehensive cancer care centers conducting preclinical and clinical research into the modulation of cancer immunity to discover the best ways to activate the immune system to recognize and eradicate cancer. Ampligen is an experimental Toll Like Receptor 3 agonist with immune modulatory properties that modify the character of patient's immunity.
News For HEB From The Last 14 Days
Check below for free stories on HEB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2014
08:39 EDTHEBHemispherx announces peer-reviewed publication on Apligen safety profile
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use